Hyperliquid Strategies Inc 8-K/A

What happened
Hyperliquid Strategies Inc. (Nasdaq: PURR) filed an amendment to its Form 8-K on Feb. 18, 2026, disclosing and attaching the audited financial statements of Sonnet BioTherapeutics Holdings, Inc. for the fiscal year ended September 30, 2025, and unaudited pro forma condensed combined financial statements showing Hyperliquid and Sonnet on a combined basis. The filing includes those documents as Exhibit 99.1 (audited Sonnet FY2025 statements) and Exhibit 99.2 (unaudited pro forma financials), plus the Inline XBRL cover page (Exhibit 104). The amendment is signed by David Schamis, Chief Executive Officer, dated Feb. 17, 2026.

Key details

• Filing type: Form 8-K Amendment (Item 9.01 — Financial Statements and Exhibits) filed Feb. 18, 2026.
• Exhibit 99.1: Sonnet BioTherapeutics Holdings, Inc. — audited financial statements for the fiscal year ended September 30, 2025 (includes Independent Auditors’ Report and notes).
• Exhibit 99.2: Unaudited pro forma condensed combined financial statements of Hyperliquid and Sonnet as of and for the period ended September 30, 2025.
• Exhibit 104: Interactive XBRL cover page embedded in the filing. Document signed by CEO David Schamis on Feb. 17, 2026.

Why it matters

• These exhibits provide investors the audited historical financials of Sonnet and the company’s pro forma combined results after the business combination, which are key to evaluating the financial impact of the acquisition on Hyperliquid (PURR).
• Audited financial statements and pro forma disclosures are common SEC requirements after a significant business combination; their availability improves transparency and helps investors assess balance sheet, revenue, expenses and potential goodwill/intangibles that resulted from the merger.
• If you own or follow PURR, look to these exhibits (99.1 and 99.2) for the detailed Sonnet income statement, balance sheet, cash flows and the assumptions used in the pro forma combination.